Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2025 16:05 ET | Quelle: Aruna Bio

Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows

BOSTON and ATHENS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the...
19. August 2024 08:00 ET | Quelle: Aruna Bio

Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain

BOSTON and ATHENS, Ga., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the...
16. Juli 2024 08:00 ET | Quelle: Aruna Bio

Aruna Bio Announces Issuance of U.S. Patent for Composition of Matter for Neural Exosomes Used to Deliver Therapeutics to the Brain

BOSTON and ATHENS, Ga., July 16, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the...
03. Juni 2024 07:00 ET | Quelle: Aruna Bio

Aruna BIO Announces Appointment of Lynn Swann to its Board of Directors

BOSTON and ATHENS, Ga., June 03, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced the...
28. Mai 2024 07:00 ET | Quelle: Aruna Bio

Aruna Bio to Present at BIO International Convention 2024

BOSTON and ATHENS, Ga., May 28, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that...
18. März 2024 08:00 ET | Quelle: Aruna Bio

Aruna Bio to Participate in Upcoming Investor Conferences

BOSTON and ATHENS, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced that...
04. März 2024 08:00 ET | Quelle: Aruna Bio

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome platform and lead program– -Phase 1b/2a clinical trial in...
16. Januar 2024 08:00 ET | Quelle: Aruna Bio

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s platform with plans to expand AB126, an unmodified exosome derived from...
10. Oktober 2023 08:00 ET | Quelle: Aruna Bio

Aruna Bio to Participate in the BIO Investor Forum in October 2023

BOSTON and ATHENS, Ga., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today...
18. September 2023 08:02 ET | Quelle: Aruna Bio

Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition

– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory and neuroprotective properties through modulation of the ATP-adenosine axis – ...

Nächste Seite